Kimberly-Clark's Q2 Earnings Top Estimates, 2025 Outlook Raised

Kimberly-Clark (KMB) reported stronger-than-expected Q2 2025 results, with adjusted EPS of $1.92 and sales of $4.16 billion both beating consensus estimates, despite year-over-year declines attributed to PPE divestitures, private-label exits, and currency headwinds. The company achieved robust 3.9% organic sales growth, driven by a 5% volume increase, underscoring effective execution of its Powering Care strategy and strong productivity. Consequently, KMB raised its full-year 2025 guidance, projecting low-to-mid single-digit growth for adjusted operating profit and EPS on a constant-currency basis, signaling management's confidence in continued underlying performance.

Analysis

Kimberly-Clark's second-quarter 2025 results demonstrate strong underlying operational performance masked by strategic portfolio adjustments. While reported sales declined 1.6% to $4.16 billion and adjusted EPS fell 2% to $1.92, both figures surpassed consensus estimates. The reported declines are directly attributable to a combined 5.4% headwind from the divestiture of its PPE business, the exit from U.S. private-label diapers, and unfavorable foreign exchange translation. The core business, however, showed significant strength, delivering 3.9% organic sales growth driven by a 5% increase in volume—the highest in five years. This volume-led growth, particularly the 5.2% increase in the key North America segment, signals successful innovation and market share gains. This strategic push for volume came at a cost to profitability, as the adjusted gross margin contracted 180 basis points to 36.9% due to planned pricing investments and tariff costs, which were not fully offset by productivity savings. Despite these margin pressures, management raised its full-year 2025 outlook, projecting low-to-mid single-digit growth in constant-currency adjusted operating profit and EPS, even after absorbing substantial headwinds from the divestitures.

Key Decisions for Investors

• Investors should look past the headline year-over-year revenue and profit declines and focus on the robust underlying metrics, particularly the 3.9% organic sales growth and the five-year high 5% volume increase, which signal strong consumer demand and successful strategy execution.
• Monitor the trade-off between volume growth and profitability, as the 180-basis-point contraction in adjusted gross margin highlights a deliberate strategy of investing in price to gain market share; the sustainability of this approach is key to achieving guided profit growth.
• The raised 2025 guidance, which projects low-to-mid single-digit EPS growth despite significant divestiture-related headwinds, warrants a re-evaluation of forward earnings models, as it implies strong management confidence in the core business's momentum and future productivity gains.
• Given the stock has outperformed its industry over the past three months (-3.5% vs -5.2%), consider the current valuation in the context of the company's successful strategic pivot toward higher-growth, branded products and its consistent capital returns to shareholders.